Global Stem Cell Therapy Market Report 2021-2030: Allogeneic Stem Cell & Therapy Autologous Stem Cell Therapy / Adult Stem Cells, Induced Pluripotent Stem Cells, & Embryonic Stem Cells

News provided by

May 19, 2021, 09:15 ET

DUBLIN, May 19, 2021 /PRNewswire/ -- The "Stem Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Stem Cell Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global stem cell therapy market.

Major players in the stem cell therapy market are Anterogen, JCR Pharmaceuticals, Medipost, Osiris Therapeutics, Pharmicell, Astellas Pharma, Cellectis, Celyad, Novadip Biosciences, and Gamida Cell.

The global stem cell therapy market is expected to grow from $8.62 billion in 2020 to $10.2 billion in 2021 at a compound annual growth rate (CAGR) of 18.3%.

The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.

The market is expected to reach $20.87 billion in 2025 at a CAGR of 20%.

The stem cell therapy market consists of the sales of stem cell therapy and related services by entities (organizations, sole traders, and partnerships) that provide stem cell therapy. Stem cell therapy, also known as regenerative medicine, promotes the repair response of diseased patient, dysfunctional or injured tissue using stem cells or their derivatives. Only goods and services traded between entities or sold to end consumers are included.

The high cost of stem cell therapy is expected to limit the growth of the stem cell therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding.

In less wealthy countries, the lack of cost-effective therapies for chronic diseases has impacted the health conditions of the population and has led to a low average life expectancy. According to the DVCSTEM, the average cost of stem cell therapy in the USA is between $20,000 to $25,000, in Mexico, it is $33,000, in Central America, it is $30,000, and in Asia, it is $50,000, thus restraining the growth of the market.

In September 2019, Vertex Pharmaceuticals Inc, a US-based biopharmaceutical company, announced its decision to acquire Semma Therapeutics, a private biotechnology company, for $950 million. The acquisition is expected to align with Vertex's strategy of investing in scientific innovation that creates transformative medicine for patients with serious diseases. Semma Therapeutics is a US-based company that is involved in using stem cell therapy for diabetes treatment.

The rising prevalence of chronic diseases contributed to the growth of the stem cell therapy market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases among people, thus driving the need for stem cell therapy. According to a United Nations article, by 2030, the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic diseases is expected to reach about 60%. The rising prevalence of chronic diseases is expected to drive the stem cell therapy market.

The companies in the stem cell therapy market are increasingly investing in strategic partnerships. The strategic partnership is a mutually beneficial agreement between two companies that do not compete directly with each other.

For instance, in September 2018, CRISPR Therapeutics, a biotechnology company that develops transformative medicine using the gene-editing platform for serious diseases, and ViaCyte, a California-based regenerative medicine company, collaborated for the development and commercialization of allogeneic stem cell therapies for diabetes treatment.

Key Topics Covered:

1. Executive Summary

2. Stem Cell Therapy Market Characteristics

3. Stem Cell Therapy Market Trends And Strategies

4. Impact Of COVID-19 On Stem Cell Therapy

5. Stem Cell Therapy Market Size And Growth
5.1. Global Stem Cell Therapy Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Stem Cell Therapy Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Stem Cell Therapy Market Segmentation
6.1. Global Stem Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Allogeneic Stem Cell Therapy
Autologous Stem Cell Therapy

6.2. Global Stem Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Adult Stem Cells
Induced Pluripotent Stem Cells
Embryonic Stem Cells

6.3. Global Stem Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Musculoskeletal Disorders
Wounds and Injuries
Cancer
Autoimmune Disorders
Others

6.4. Global Stem Cell Therapy Market, Segmentation By End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Hospitals

7. Stem Cell Therapy Market Regional And Country Analysis
7.1. Global Stem Cell Therapy Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Stem Cell Therapy Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

Anterogen
JCR Pharmaceuticals
Medipost
Osiris Therapeutics
Pharmicell
Astellas Pharma
Cellectis
Celyad
Novadip Biosciences
Gamida Cell
Capricor Therapeutics
Cellular Dynamics
CESCA Therapeutics
DiscGenics
OxStem
Mesoblast
ReNeuron Group
Takeda Pharmaceuticals
Magellan
Kolon TissueGene
Stemedica Cell Technologies
Holostem Terapie Avanzate S.r.l.
NuVasive
RTI Surgical
AlloSource

For more information about this report visit https://www.researchandmarkets.com/r/7faivn

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets